The objective of this study is to investigate the surgical, clinical and pathological outcomes of left hemi-hepatectomy during cytoreductive surgery (CRS) in patients with primary ovarian cancer. The electronic medical charts of patients with primary ovarian cancer who received CRS including left hemi-hepatectomy from 2000 to 2023 were reviewed and retrospectively analyzed. A total of 17 patients underwent left hemi-hepatectomy for resection of a deep peritoneal implant in the round ligament of the liver during primary CRS. Among these 17 patients, hepatic parenchymal invasion was confirmed in 10 patients (58.8%). Tumor distribution of others is as follows: Glisson’s capsule, hilum, falciform ligament and gall bladder. Fourteen patients (82.4%) achieved CRS; the remaining three patients had residual tumors less than 1 cm. The median period to subsequent chemotherapy was 21 days (range, 12–35 days). No specific complications related to left hepatectomy were identified such as liver failure or bile leakage. Left hemi-hepatectomy for complete surgical resection of a deep peritoneal implant of the round ligament of the liver is surgically feasible and safe.
本研究旨在探讨原发性卵巢癌患者在接受肿瘤细胞减灭术（CRS）期间进行左半肝切除术的手术、临床及病理学结果。研究回顾并分析了2000年至2023年间接受包含左半肝切除术的CRS治疗的原发性卵巢癌患者的电子病历资料。共有17例患者在初次CRS中为切除肝脏圆韧带深部腹膜种植灶接受了左半肝切除术。在这17例患者中，10例（58.8%）经病理证实存在肝实质侵犯。其余患者的肿瘤分布情况如下：Glisson鞘、肝门、镰状韧带及胆囊。14例患者（82.4%）达到完全肿瘤减灭；剩余3例患者残留肿瘤直径小于1厘米。术后至开始后续化疗的中位时间为21天（范围：12-35天）。未发现与左半肝切除术相关的特定并发症，如肝功能衰竭或胆漏。为彻底切除肝脏圆韧带深部腹膜种植灶而实施的左半肝切除术具有手术可行性且安全性良好。
肿瘤(癌症)患者之家